BioGaia AB Class B ((GB:0GTN)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioGaia AB is currently conducting a clinical study titled ‘A Double-blind, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic.’ The study aims to assess the impact of the probiotic L. reuteri on reducing crying and fussing time in infants suffering from colic, a common condition causing discomfort and distress in newborns.
The intervention being tested is a dietary supplement containing L. reuteri, administered as drops daily over a 21-day period. The study also includes a placebo group receiving identical drops without the probiotic, allowing for a clear comparison of results.
This study employs a randomized, parallel-group design with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of group assignments. The primary purpose is treatment-focused, aiming to provide evidence on the effectiveness of L. reuteri in managing infantile colic symptoms.
The study began on June 12, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 23, 2025, indicating ongoing recruitment and progress.
For investors, the successful outcome of this study could enhance BioGaia’s market position, potentially boosting stock performance and investor confidence. As the demand for effective colic treatments grows, BioGaia’s advancements could set it apart from competitors in the probiotic industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.